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Abstract  
A 16 years old female patient, affected by atopic dermatitis and rhinoconjunctivitis allergica since childhood, 
requested a dermatologic consultation for lesions which had appeared after 3 months of local treatment with 
clobethasole propionate. The histological analysis confirmed the diagnosis of dyshidrotic eczema and the 
microbiological smears demonstrated a significant infection with Staphylococcus aureus. The risk of developing 
corticosteroids’ side-effects depends on the potency of the product, extended period of use and the volume of 
product applied. Clobetasol propionate is a group I- highly potent corticosteroid, which should be used for a 
maximum period of 2 weeks. Several authors have found that this agent has cumulative depot effect, persisting in 
the epidermis for 4 days after only one application. Taking together these observations, sustained by the clinical 
case presented above, we can conclude that the infectious risks associated with topical corticosteroid treatment 
must not be neglected, particularly since treated patients are fragile, and frequently have multiple well-known risk 
factors. 
 
 
 
 
 
 
 
 
 
 
A 16 years old female patient, affected by 
atopic dermatitis and rhinoconjunctivitis allergica since 
childhood, requested a dermatologic consultation for 
the lesions presented in Fig. 1a, 1b, which had 
appeared after 3 months of local treatment with 
clobethasole propionate for dyshidrotic eczema. The 
histological analysis confirmed the diagnosis of 
dyshidrotic eczema and the microbiological smears 
demonstrated a significant infection with 
Staphylococcus aureus. The pictures show the corpus 
inflammation and maceration of the skin (Fig. 1a, 1b). 
After a 10 days treatment regimen with systemic 
antibiotics (Clarithromycin Retard 500 mg once daily), 
antihistamine tablets (Bilastine 20 mg) and topical 
antibacterial agents (silver sulfadiazine), the 
symptomatology improved significantly.  
This complex case reveals a significant 
immune system dysregulation since the patient had 
been affected by atopic dermatitis and 
rhinoconjunctivitis allergica for a long period. As 
demonstrated by Ambach A et al., these pathologies 
can be linked to T-cell dysfunction [1]. 
The risk of cutaneous infections due to topical 
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corticosteroids is known but has never been 
thoroughly studied [2]. Z. Boughrara et al. noted 
cutaneous super-infection in nine of 30 patients 
receiving topical corticosteroids for bullous 
pemphigoid, among which there were three cases of 
fatal necrotizing fasciitis due to Streptococcus A [2].  
The risk of developing corticosteroids’ side-
effects depends on the potency of the product, 
extended period of use and the volume of product 
applied [6]. Clobetasol propionate is a group I- highly 
potent corticosteroid, which should be used for a 
maximum period of 2 weeks [6]. Research has found 
that this agent has cumulative depot effect, persisting 
in the epidermis for 4 days after only one application 
[3]. Recently, del Rosso highlighted the fact that 
topical corticosteroids may disrupt the lipid synthesis 
in stratum corneum, interfering with epidermal barrier 
recovery [4]. 
 
Figure 1: Clinical pictures of a female patient with macerated 
dyshidrotic eczema and massive superinfection with St. aureus. 
Yellow-brown colour of the lesions and massive edema 
 
The biomolecular events that facilitate the 
infection suggest a systemic dysfunction, not limited to 
the skin district. Indeed, Boudhir H et al. underlined 
that nodular lesions of Kaposi's disease appeared 
during treatment of bullous pemphigoid with topical 
corticosteroids [5].  
Taking together these observations, evoked 
after the analysis of the clinical case, indicate that the 
infectious risks associated with topical corticosteroid 
treatment must not be neglected, particularly since 
treated patients are fragile, and frequently have 
multiple well-known risk factors.  
Taking together these observations, sustained 
by the clinical case presented above, we can 
conclude that the infectious risks associated with 
topical corticosteroid treatment must not be neglected, 
particularly since treated patients are fragile, and 
frequently have multiple well-known risk factors. 
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